Compare Nuvalent Inc (NUVL) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvalent Inc vs Wells Fargo & Co — how do they compare? Nuvalent Inc trades at $123.96 (market cap $9.81B), while Wells Fargo & Co trades at $87.15 (market cap $261.45B). The key difference: Wells Fargo & Co is far larger — about 26.7× Nuvalent Inc's market cap, and Wells Fargo & Co pays a 2.09% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| NUVL | WFC | |
|---|---|---|
Market Cap | $9.81B | $261.45B |
Sector | Technology | Financials |
52-Week High | $123.96 | $96.40 |
52-Week Low | $72.16 | $73.42 |
Enterprise Value | $8.52B | — |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nuvalent (NUVL) trades at $123.96, showing no change recently, with technical indicators presenting a mixed signal—moving averages are bullish while oscillators are bearish. The company reported a net loss of $425.38 million for 2025, with negative profitability metrics like ROE of -41.19%. Recent news highlights GSK's proposed acquisition of Nuvalent for $124 per share, totaling $10.6 billion, which is under investigation by multiple law firms for fairness concerns.
The investment outlook is heavily influenced by the pending acquisition, offering a near-term exit at $124 per share. However, risks include ongoing financial losses, negative cash flow from operations, and legal scrutiny over the deal's adequacy. Analyst sentiment is mixed with 42% buy ratings, but the acquisition provides a clear valuation anchor amid fundamental challenges.
Wells Fargo (WFC) trades at $87.75, up 0.26% today, with a neutral technical signal and bullish moving averages. The stock shows improving fundamentals with 2025 revenue of $83.70B and net income of $21.34B, yielding a 25.97% net margin. Recent Q2 2026 earnings beat expectations with EPS of $1.96 versus $1.73 expected. Analyst consensus is mixed with a $97.36 price target, suggesting 11% upside. The bank continues growth initiatives post-asset cap removal, though net cash flow remains negative.
Outlook remains cautiously optimistic given valuation support (P/E 12.55) and dividend yield, but risks include net interest margin pressure and volatile cash flows. Institutional activity is mixed with some trimming positions. Earnings sustainability and loan growth execution are key catalysts for further upside, while macroeconomic sensitivity poses a headwind.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
